Lung Cancer, Non-small Cell Clinical Trial
— Onco-VOCOfficial title:
Volatil Organic Compounds in Exhaled Air and Sweat After Thoracic Surgery for Carcinological Resection
Bronchopulmonary cancer, with 39 000 new cases and 30 000 deaths per year, is a main issue in public health in France. It is the leading cause of cancer death in France. A lot of progress in medical care has been made, but surgery remains the most effective treatment, when it is still possible. The goal is to detect and manage the lung cancer as early as possible. Alongside screening strategies by annual thoracic scanner, new approaches with innovative technologies open up for cancer detection and therapeutic follow-up. The study of volatile organic compounds (VOC) detected in exhaled air or in sweat, is an innovative research area for respiratory diseases. The volatolomic analysis can be done either by the technique of the mass spectrometry which allows the identification of each VOC in the exhaled air or by the technique of electronic nose, simpler and faster, which provides an idea of the general profile of the VOC without identifying them. The VOC have shown their interest in some situations, such as diagnostic or prognostic tool in patients followed for thoracic tumorous pathology or bronchial or pulmonary vascular diseases. The composition of VOC in exhaled air and sweat is altered in patients with lung cancer. The VOC analysis and their variation could be used particularly in the follow-up of patients treated for lung cancer. The purpose of this clinical research is to identify the VOCs related to lung cancers by comparing the VOC profiles in exhaled air and in sweat from patients diagnosed with localized lung cancer before and after resection surgery.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | September 2021 |
Est. primary completion date | September 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patient aged = 18 years old - Patient with non-small cell lung cancer - Operable grade I or II - No specific treatment before surgery (radiotherapy, chemotherapy or targeted therapy) - Patient with healthcare insurance Non Inclusion Criteria: - Treatment with radiotherapy, chemotherapy, or neoadjuvant cancer targeted therapy before thoracic surgery - Patient with oxygen therapy or invasive ventilation - Patient unable to perform a slow vital capacity - Dermatological therapy interfering with sweat collection (psoriasis, irritant dermatitis, for instance) - Pregnant women - Patient deprived of liberty by judicial or administrative decision |
Country | Name | City | State |
---|---|---|---|
France | Hôpital Foch | Suresnes |
Lead Sponsor | Collaborator |
---|---|
Hopital Foch |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Comparison of Volatil Organic Compound (VOC) profiles by mass spectrometry | Comparison of variation in Volatil Organic Compound (VOC) profiles in exhaled air of patients before and after surgery. The VOC will be identified by their molecular mass (by the mass spectrometry) | change from baseline profiles at 2 month post-surgery | |
Primary | Comparison of Volatil Organic Compound (VOC) profiles in by electronic noses | Comparison of variation in Volatil Organic Compound (VOC) profiles in exhaled air of patients before and after surgery. The VOC will be identified by the sensor deflection (by the electronic noses). | change from baseline profiles at 2 month post-surgery | |
Secondary | Comparison of Volatil Organic Compound (VOC) profiles in sweat | Comparison of Volatil Organic Compound (VOC) profiles in sweat of patients before and after surgery. The VOC will be identified by their molecular mass (by the mass spectrometry). | 30 days before the surgery and 45 to 75 days after surgery | |
Secondary | Variation of Volatil Organic Compound (VOC) and relapse rate | Correlation between the variation of Volatil Organic Compound (VOC) before-after surgery and relapse rate at 2 years | 30 days before the surgery, 45 to 75 days after surgery and 2 years | |
Secondary | Correlation between Volatil Organic Compound (VOC) profiles and relapse rate | Correlation between the Volatil Organic Compound (VOC) profiles 2 months after the surgery and relapse rate at 2 years | 2 months and 2 years after surgery | |
Secondary | Comparison of Volatil Organic Compound (VOC) profiles in exhaled air and tumoral lung tissue | Comparison of Volatil Organic Compound (VOC) profiles in exhaled air of patients and those released ex-vivo by the tumoral lung tissue. The VOC will be identified by their molecular mass (by the mass spectrometry). | 30 days before the surgery, day of surgery and 45 to 75 days after surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05598528 -
Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)
|
||
Completed |
NCT03836469 -
Retrospective Epidemiological Study of Locally Advanced Non Small Cell Lung Cancer Patients in Brazil
|
||
Completed |
NCT01772225 -
NSCLC Burden of Illness Study
|
N/A | |
Completed |
NCT01362296 -
An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01460472 -
Immunotherapy With Racotumomab in Advanced Lung Cancer
|
Phase 3 | |
Completed |
NCT00528281 -
A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase
|
Phase 1 | |
Not yet recruiting |
NCT04592666 -
Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer
|
Phase 2 | |
Terminated |
NCT00480025 -
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
|
Phase 3 | |
Active, not recruiting |
NCT05784142 -
Chemo-immunotherapy Induction Followed by Hypo-radiotherapy in LA-NSCLC(CHIC)
|
Phase 2 | |
Active, not recruiting |
NCT04475939 -
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer
|
Phase 3 | |
Withdrawn |
NCT01938456 -
Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer
|
Phase 1 | |
Terminated |
NCT04069936 -
Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC
|
Phase 2 | |
Recruiting |
NCT05565378 -
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04986670 -
NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer
|
N/A | |
Completed |
NCT00367679 -
Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer
|
Phase 2 | |
Terminated |
NCT00073008 -
A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04581824 -
Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
|
Phase 2 | |
Completed |
NCT00619424 -
A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04940936 -
Shared Decision Making on Radiation Dose for Lung Malignancies
|
N/A | |
Recruiting |
NCT02824952 -
Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLC
|
Phase 2 |